(ILMN) Illumina - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4523271090
Stock: Sequencers, Arrays, Reagents, Kits, Services
Total Rating 46
Risk 67
Buy Signal 0.05
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 43.6% |
| Relative Tail Risk | -5.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.33 |
| Alpha | -7.92 |
| Character TTM | |
|---|---|
| Beta | 1.125 |
| Beta Downside | 0.873 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.94% |
| CAGR/Max DD | -0.17 |
Description: ILMN Illumina January 02, 2026
Illumina (NASDAQ: ILMN) develops and sells sequencing- and array-based platforms and consumables for genomic analysis across a global customer base that includes research institutions, clinical labs, pharma/biotech firms, and consumer-genomics companies. Its product portfolio spans next-generation sequencing instruments, whole-genome and targeted-sequencing kits, genotyping arrays, and non-invasive prenatal testing solutions, supported by reagent kits, flow cells, and library-prep services.
Key recent metrics: 2023 revenue reached $5.6 billion, up ~9 % YoY, driven by a 15 % increase in consumables sales as sequencing-throughput volumes rise. The company’s cost-per-genome has fallen below $200, reinforcing its competitive edge in the rapidly expanding clinical-diagnostics market, where NGS adoption is projected to grow at a CAGR of ~20 % through 2030. A notable sector driver is the surge in personalized-medicine pipelines, which fuels demand for high-throughput, low-error-rate sequencing platforms.
For a deeper, data-focused assessment of Illumina’s valuation dynamics, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 703.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 7.22 > 1.0 |
| NWC/Revenue: 19.45% < 20% (prev 31.85%; Δ -12.39% < -1%) |
| CFO/TA 0.18 > 3% & CFO 1.12b > Net Income 703.0m |
| Net Debt (1.53b) to EBITDA (1.29b): 1.18 < 3 |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.0m) vs 12m ago -1.88% < -2% |
| Gross Margin: 66.20% > 18% (prev 0.64%; Δ 6556 % > 0.5%) |
| Asset Turnover: 70.33% > 50% (prev 73.00%; Δ -2.67% > 0%) |
| Interest Coverage Ratio: 8.16 > 6 (EBITDA TTM 1.29b / Interest Expense TTM 125.0m) |
Altman Z'' 1.42
| A: 0.14 (Total Current Assets 2.80b - Total Current Liabilities 1.96b) / Total Assets 6.18b |
| B: -0.12 (Retained Earnings -726.0m / Total Assets 6.18b) |
| C: 0.17 (EBIT TTM 1.02b / Avg Total Assets 6.10b) |
| D: -0.19 (Book Value of Equity -736.0m / Total Liabilities 3.80b) |
| Altman-Z'' Score: 1.42 = BB |
Beneish M -3.12
| DSRI: 1.08 (Receivables 751.0m/715.0m, Revenue 4.29b/4.39b) |
| GMI: 0.97 (GM 66.20% / 63.94%) |
| AQI: 0.93 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 0.98 (Revenue 4.29b / 4.39b) |
| TATA: -0.07 (NI 703.0m - CFO 1.12b) / TA 6.18b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of ILMN shares?
As of February 02, 2026, the stock is trading at USD 144.81 with a total of 2,421,586 shares traded.
Over the past week, the price has changed by -5.35%, over one month by +7.79%, over three months by +20.69% and over the past year by +10.46%.
Over the past week, the price has changed by -5.35%, over one month by +7.79%, over three months by +20.69% and over the past year by +10.46%.
Is ILMN a buy, sell or hold?
Illumina has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold ILMN.
- StrongBuy: 7
- Buy: 5
- Hold: 11
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the ILMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 135.9 | -6.1% |
| Analysts Target Price | 135.9 | -6.1% |
| ValueRay Target Price | 147.6 | 1.9% |
ILMN Fundamental Data Overview January 31, 2026
P/E Trailing = 33.5628
P/E Forward = 29.5858
P/S = 5.3655
P/B = 9.6063
P/EG = 0.622
Revenue TTM = 4.29b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 24.53b USD (23.01b + Debt 2.58b - CCE 1.05b)
Interest Coverage Ratio = 8.16 (Ebit TTM 1.02b / Interest Expense TTM 125.0m)
EV/FCF = 24.36x (Enterprise Value 24.53b / FCF TTM 1.01b)
FCF Yield = 4.10% (FCF TTM 1.01b / Enterprise Value 24.53b)
FCF Margin = 23.49% (FCF TTM 1.01b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.97 (Enterprise Value 24.53b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 695.5m (EBIT 1.02b * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.18 (Net Debt 1.53b / EBITDA 1.29b)
Debt / FCF = 1.52 (Net Debt 1.53b / FCF TTM 1.01b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.53% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 30.55% (EBIT 1.02b / Capital Employed (Equity 2.35b + L.T.Debt 994.0m))
RoIC = 16.04% (NOPAT 695.5m / Invested Capital 4.34b)
WACC = 9.18% (E(23.01b)/V(25.58b) * Re(10.06%) + D(2.58b)/V(25.58b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 73.97% ; FCFF base≈822.6m ; Y1≈826.5m ; Y5≈883.5m
Fair Price DCF = 72.57 (EV 12.62b - Net Debt 1.53b = Equity 11.09b / Shares 152.8m; r=9.18% [WACC]; 5y FCF grow 0.0% → 2.90% )
EPS Correlation: 28.22 | EPS CAGR: -60.17% | SUE: -4.0 | # QB: 0
Revenue Correlation: -75.73 | Revenue CAGR: -2.68% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.13 | Chg30d=+0.015 | Revisions Net=+0 | Analysts=11
EPS next Year (2026-12-31): EPS=5.07 | Chg30d=+0.059 | Revisions Net=+2 | Growth EPS=+7.2% | Growth Revenue=+2.7%
P/E Forward = 29.5858
P/S = 5.3655
P/B = 9.6063
P/EG = 0.622
Revenue TTM = 4.29b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 24.53b USD (23.01b + Debt 2.58b - CCE 1.05b)
Interest Coverage Ratio = 8.16 (Ebit TTM 1.02b / Interest Expense TTM 125.0m)
EV/FCF = 24.36x (Enterprise Value 24.53b / FCF TTM 1.01b)
FCF Yield = 4.10% (FCF TTM 1.01b / Enterprise Value 24.53b)
FCF Margin = 23.49% (FCF TTM 1.01b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.97 (Enterprise Value 24.53b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 695.5m (EBIT 1.02b * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.18 (Net Debt 1.53b / EBITDA 1.29b)
Debt / FCF = 1.52 (Net Debt 1.53b / FCF TTM 1.01b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.53% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 30.55% (EBIT 1.02b / Capital Employed (Equity 2.35b + L.T.Debt 994.0m))
RoIC = 16.04% (NOPAT 695.5m / Invested Capital 4.34b)
WACC = 9.18% (E(23.01b)/V(25.58b) * Re(10.06%) + D(2.58b)/V(25.58b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 73.97% ; FCFF base≈822.6m ; Y1≈826.5m ; Y5≈883.5m
Fair Price DCF = 72.57 (EV 12.62b - Net Debt 1.53b = Equity 11.09b / Shares 152.8m; r=9.18% [WACC]; 5y FCF grow 0.0% → 2.90% )
EPS Correlation: 28.22 | EPS CAGR: -60.17% | SUE: -4.0 | # QB: 0
Revenue Correlation: -75.73 | Revenue CAGR: -2.68% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.13 | Chg30d=+0.015 | Revisions Net=+0 | Analysts=11
EPS next Year (2026-12-31): EPS=5.07 | Chg30d=+0.059 | Revisions Net=+2 | Growth EPS=+7.2% | Growth Revenue=+2.7%